Overexpression of KLF4 in mgR SMCs normalized expression of contractile markers. by Matthew Dale (4518433)

Comparative analysis of AR, SOX9 and AMH expression in adult human testes representing androgen-insensitivity syndrome (AIS), Sertoli-cell-only syndrome (SCOS), and normal spermato... by Kuo-Chung Lan (465113)

Data_Sheet_1_Source Contribution of Firecrackers Burst vs. Long-Range Transport of Biomass Burning Emissions Over an Urban Background.docx by Prashant Rajput (4777776)

“…The wind pattern and cluster analysis have revealed a quite similar feature that from 10th to 16th of November the prevailed winds were north-westerly (NW). …”

Extensive Natural Variation for Cellular Hydrogen Peroxide Release Is Genetically Controlled by Homa Attar (138799)

“…We did not find replication of SNPs across all cohorts, but replication within the same genomic region. Finally, a highly significant decrease in H₂O₂ release was observed in Down Syndrome (DS) individuals (p<2.88×10−12). …”

Alterations in Vitamin E of obese horses. by Michelle C. Coleman (2172151)

Co-immunoprecipitation experiments to examine the interactions of beclin-1 with Bcl-2 and Bcl-xL. by Tai-Ho Hung (306051)

Time Evolution of Joint Probability Distribution by Tim Herpich (4796655)

Decrement in serum total and LDL-cholesterol in statin group (SG) and nonstatin group (NSG) during 12 months GH replacement by John P Monson (80972)

Differential changes in the transcription of Bcl-2, Bcl-xL, Bax and Bak. by Tai-Ho Hung (306051)

The expression analysis of selected genes from the RNA-seq by relative quantitative real-time PCR. by Yunyan Deng (155524)

Video_2_Expression of placental CD146 is dysregulated by prenatal alcohol exposure and contributes in cortical vasculature development and positioning of vessel-associated oligoden... by Camille Sautreuil (17766633)

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”